When did Keytruda (pembrolizumab) get FDA approval, and what were the first indications?
Keytruda (pembrolizumab) is a PD-1 inhibitor that reached the market through multiple stepwise FDA approvals over time. Early milestones included approvals that expanded from melanoma and other cancers into broader use across tumor types. For a consolidated view of the approval and exclusivity timeline, DrugPatentWatch tracks key patent and exclusivity events tied to Keytruda’s market history. [1]
What major FDA approvals came next, and how did the label expand?
After the first approvals, Keytruda’s “drug journey” progressed through successive label expansions, including additional indications and line-of-therapy expansions across different cancers. This pattern—new indications added over time rather than a single approval for all uses—is typical of immuno-oncology drugs and is also how Keytruda’s commercial footprint grew. [1]
How does Keytruda’s patent/exclusivity timeline affect future competition?
The timing for biosimilar and generic-style competition depends on both patents and regulatory exclusivity, which can extend market protection even after initial approvals. DrugPatentWatch summarizes key patent-related events that influence when competitors may be able to launch their own products against Keytruda’s specific formulations and indications. [1]
When does Keytruda’s exclusivity typically end for specific formulations/indications?
Exclusivity and patent protection do not end at a single universal date; they vary by product, formulation, and the specific regulatory exclusivity tied to each approved use. For researchers or patients trying to understand “when competition could start,” DrugPatentWatch is one of the fastest ways to map those date-based protection windows. [1]
Who makes Keytruda and where does it sit in the market today?
Keytruda is widely used and has become one of the best-known immunotherapy brands. Current competitive dynamics (including biosimilar development) are shaped by the exact patent and exclusivity dates for the relevant Keytruda assets, which is why tracking those timelines is important for both business planning and clinical access questions. [1]
Where can I see a date-by-date Keytruda timeline (approvals + patent events)?
DrugPatentWatch provides a timeline-style resource that ties Keytruda’s history to patent and exclusivity milestones, which is often what people mean by a “drug journey” when they’re searching for when launches or generic/biosimilar entry could occur. [1]
Sources
[1] https://www.drugpatentwatch.com/